Evidence map›Paper›PMID 41137548›Full record

ArticleBiotechnology and bioengineering2026

Downstream Process Intensification for AAV Purification by Affinity Chromatography Using Single Pass Tangential Flow Filtration.

Akshay S Chaubal, Ronny Horax, Christopher J Yehl, S Ranil Wickramasinghe, Xianghong Qian, Lu Wang, Andrew L Zydney

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Akshay S ChaubalDepartment of Chemical Engineering, Pennsylvania State University, University Park, Pennsylvania.
Ronny HoraxDepartment of Biomedical Engineering, University of Arkansas, Fayetteville, Arkansas.
Christopher J YehlGene Therapy Purification Development, Roche, Philadelphia, Pennsylvania.
S Ranil WickramasingheDepartment of Chemical Engineering, University of Arkansas, Fayetteville, Arkansas.
Xianghong QianDepartment of Biomedical Engineering, University of Arkansas, Fayetteville, Arkansas.ORCID 0000-0001-5619-9782
Lu WangGene Therapy Purification Development, Roche, Philadelphia, Pennsylvania.
Andrew L ZydneyDepartment of Chemical Engineering, Pennsylvania State University, University Park, Pennsylvania.ORCID 0000-0003-1865-9156

Funding

Support for this study was provided through the Membrane Applications Science and Technology (MAST) Center, funded by grant numbers 2310832 and 2310905 from the National Science Foundation's IUCRC program. Additional funding support from National Science Foundation EPSCoR Track 2 (RII 2218054) is also gratefully acknowledged.
6 · The paper itself

Abstract

To enable adeno-associated viral vectors (AAV) to achieve their maximum potential, next-generation manufacturing processes must be developed to make gene therapies more affordable and accessible. This study focused on the design of two different intensified AAV downstream manufacturing processes at bench and pilot scale. Novel clarification methods were studied at bench scale, including the use of BioOptimal™ MF-SL tangential flow microfilters for continuous removal of cell debris. Membrane adsorbers were used for further clarification, including DNA removal. Single pass tangential flow filtration (SPTFF) was implemented at bench scale by feeding the clarified cell lysate (CCL) into two Pellicon XL50 cassettes with 100 kDa regenerated cellulose membranes. At pilot scale, a multi-membrane staged SPTFF module was designed to concentrate 10 L of AAV CCL. Both SPTFF systems provided 12X inline volumetric concentration with AAV yield > 99% after an appropriate buffer chase. Host cell protein removal was 48% and 37% for the bench and pilot scale processes, respectively. As an initial proof-of-concept, an integrated process was developed at pilot-scale which linked clarification, SPTFF, and affinity chromatography. The integrated process offered an 81% reduction in total operating time (due to the reduced volume of load material for the affinity column after preconcentration by SPTFF), 36% improvement in affinity resin utilization (due to the higher AAV concentration in the column load), and an estimated 10% reduction in raw material costs. These improvements translated to an 8.5-fold increase in overall productivity compared to an equivalent batch process, underscoring the potential for SPTFF to intensify large-scale AAV downstream processing.

Indexed as

Chromatography, AffinityDependovirusFiltrationGenetic VectorsHumansAdeno‐associated virus (AAV)affinity chromatographyclarificationcontinuous processingprocess intensificationSingle pass tangential flow filtration

Identifiers

PMID41137548
PMCPMC12699131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.